Lumos Pharma Receivables

Lumos Pharma (LUMO) currently reports a receivables of $170K as of September 2024. That compares with $170K in the prior-year period — up 1.2% year over year. Use the charts on this page to explore Lumos Pharma's receivables history and peer comparisons.

Lumos Pharma's receivables increased from $170K to $170K — a 1.2% year-over-year increase (period ending September 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Lumos Pharma reported $170K in receivables as of September 2024. That compares with $170K in the prior-year period — up 1.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $170K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Lumos Pharma, and consider following LUMO for alerts when major investors trade the stock.

Lumos Pharma is classified in the Healthcare sector. On receivables, it currently shows $170K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LUMO with unrelated industries.